KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Guardant Health (GH) Research & Development: 2017-2025

Historic Research & Development for Guardant Health (GH) over the last 8 years, with Sep 2025 value amounting to $90.0 million.

  • Guardant Health's Research & Development rose 3.04% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $359.5 million, marking a year-over-year increase of 4.48%. This contributed to the annual value of $347.8 million for FY2024, which is 5.29% down from last year.
  • Latest data reveals that Guardant Health reported Research & Development of $90.0 million as of Q3 2025, which was up 2.87% from $87.4 million recorded in Q2 2025.
  • Over the past 5 years, Guardant Health's Research & Development peaked at $106.6 million during Q4 2022, and registered a low of $55.5 million during Q1 2021.
  • Moreover, its 3-year median value for Research & Development was $89.9 million (2023), whereas its average is $89.2 million.
  • In the last 5 years, Guardant Health's Research & Development surged by 95.80% in 2021 and then declined by 15.69% in 2023.
  • Over the past 5 years, Guardant Health's Research & Development (Quarterly) stood at $73.0 million in 2021, then surged by 45.96% to $106.6 million in 2022, then dropped by 15.69% to $89.9 million in 2023, then grew by 4.10% to $93.5 million in 2024, then increased by 3.04% to $90.0 million in 2025.
  • Its Research & Development was $90.0 million in Q3 2025, compared to $87.4 million in Q2 2025 and $88.5 million in Q1 2025.